Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
05:34am, Monday, 14'th Oct 2024
Buying these stocks gives you a great chance to beat the benchmark.
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.
05:40am, Saturday, 12'th Oct 2024
This Dividend King is beyond Buffett's reach to fully acquire and is a great pick for income investors.
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
07:46am, Friday, 11'th Oct 2024
AbbVie NYSE: ABBV spooked the market in early October, but the sell-off is a buying opportunity. The critical takeaway is that only the earnings guidance was altered; the trim was small and offset by
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
01:15pm, Wednesday, 09'th Oct 2024
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:08am, Wednesday, 09'th Oct 2024
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Undervalued Dividend Kings: October 2024
09:00am, Tuesday, 08'th Oct 2024
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for pote
3 Magnificent Dividend Stocks to Buy in October
05:50am, Sunday, 06'th Oct 2024
These dividend stocks are great picks as the fall season gets underway.
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
04:31am, Sunday, 06'th Oct 2024
Declining earnings haven't scared billionaire investors away from this stock.
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
06:15am, Saturday, 05'th Oct 2024
These companies can lend growth and dividend returns to a long-term investor's portfolio.
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
10:15am, Friday, 04'th Oct 2024
ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
06:51pm, Thursday, 03'rd Oct 2024
AbbVie (ABBV) closed the most recent trading day at $195.45, moving -0.7% from the previous trading session.
AbbVie cuts 2024 profit forecast on R&D expenses
04:16pm, Thursday, 03'rd Oct 2024
AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing $82 million in milestones, and research and development expenses related to acquisitions.
AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia
12:04pm, Thursday, 03'rd Oct 2024
AbbVie's acquisition of Cerevel Therapeutics enhances its neuroscience pipeline with promising candidates Emraclidine and Tavapadon, expected to significantly boost revenues post-approval. Emraclidine
3 Top Pharma Stocks to Buy in October 2024
08:11am, Thursday, 03'rd Oct 2024
The pharmaceutical industry plays a crucial role in most of our everyday lives.
AbbVie: A Strong Investment Opportunity In Neurological And Oncology Breakthroughs
08:00am, Thursday, 03'rd Oct 2024
AbbVie presents a strong long-term investment opportunity, driven by its strategic focus on neuroscience and IBD treatments, despite challenges from Humira's decline. Tavapadon and other neuroscience
